» Articles » PMID: 22086675

Effect of Silibinin in Human Colorectal Cancer Cells: Targeting the Activation of NF-κB Signaling

Overview
Journal Mol Carcinog
Date 2011 Nov 17
PMID 22086675
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic inflammation is one of the primary causes of colorectal cancer (CRC), and major inflammatory pathways implicated in CRC are cyclooxygenase-2 (COX-2) and iNOS; both regulated by nuclear factor-kappa B (NF-κB) suggesting that inhibitors of these pathways could be ideal against CRC. Silibinin has shown promising efficacy against various malignancies including CRC, and therefore here we assessed whether silibinin targets NF-κB activation and associated signaling as a mechanism of its anti-inflammatory and anti-cancer effects in CRC. Our results indicated that silibinin treatment (50-200 µM) of human CRC SW480, LoVo, and HT29 cells strongly inhibits tumor necrosis factor α-induced NF-κB activation together with decreased nuclear levels of both p65 and p50 sub-units. Silibinin also significantly increased IκBα level with a concomitant decrease in phospho-IκBα, without any effect on TNFR1, TRADD, and RIP2, indicating its inhibitory effect on IκB kinase α activity. Next we assessed the effect of oral silibinin feeding on NF-κB pathway in SW480 (COX-2 negative) and LoVo (COX-2 positive) tumor xenografts in nude mice. Together with its inhibitory efficacy on tumor growth and progression, silibinin inhibited NF-κB activation in both xenografts. The protein levels of various NF-κB-regulated molecules such as Bcl-2, COX-2, iNOS, VEGF, and MMPs were also decreased by silibinin in both cell culture studies and xenograft analyses, suggesting its potential to alter NF-κB transcriptional activity. Together, these findings are highly significant in establishing for the first time that silibinin suppresses CRC growth and progression possibly through its anti-inflammatory activity by interfering with NF-κB activation and thus has potential against human CRC.

Citing Articles

Therapeutic potential of flavonoids in gastrointestinal cancer: Focus on signaling pathways and improvement strategies (Review).

Ding Y, Yu Y Mol Med Rep. 2025; 31(4).

PMID: 40017144 PMC: 11884236. DOI: 10.3892/mmr.2025.13474.


Flavonoids and Flavonoid-Based Nanopharmaceuticals as Promising Therapeutic Strategies for Colorectal Cancer-An Updated Literature Review.

Smeu A, Marcovici I, Dehelean C, Dumitrel S, Borza C, Lighezan R Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006045 PMC: 11858883. DOI: 10.3390/ph18020231.


Management of Colorectal Cancer Using Nanocarriers-based Drug Delivery for Herbal Bioactives: Current and Emerging Approaches.

Deshmukh R, Prajapati M, Harwansh R Curr Pharm Biotechnol. 2024; 25(5):599-622.

PMID: 38807329 DOI: 10.2174/0113892010242028231002075512.


Silymarin and Inflammation: Food for Thoughts.

Surai P, Surai A, Earle-Payne K Antioxidants (Basel). 2024; 13(1).

PMID: 38247522 PMC: 10812610. DOI: 10.3390/antiox13010098.


Bioactive Compounds of Dietary Origin and Their Influence on Colorectal Cancer as Chemoprevention.

Delgado-Gonzalez P, Garza-Trevino E, de la Garza Kalife D, Quiroz Reyes A, Hernandez-Tobias E Life (Basel). 2023; 13(10).

PMID: 37895359 PMC: 10608661. DOI: 10.3390/life13101977.


References
1.
Gu M, Singh R, Dhanalakshmi S, Agarwal C, Agarwal R . Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Res. 2007; 67(7):3483-91. DOI: 10.1158/0008-5472.CAN-06-3955. View

2.
Tyagi A, Raina K, Singh R, Gu M, Agarwal C, Harrison G . Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther. 2007; 6(12 Pt 1):3248-55. DOI: 10.1158/1535-7163.MCT-07-2006. View

3.
Singh R, Dhanalakshmi S, Mohan S, Agarwal C, Agarwal R . Silibinin inhibits UVB- and epidermal growth factor-induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-kappaB in mouse epidermal JB6 cells. Mol Cancer Ther. 2006; 5(5):1145-53. DOI: 10.1158/1535-7163.MCT-05-0478. View

4.
Agarwal C, Singh R, Dhanalakshmi S, Tyagi A, Tecklenburg M, Sclafani R . Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene. 2003; 22(51):8271-82. DOI: 10.1038/sj.onc.1207158. View

5.
Danese S, Mantovani A . Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene. 2010; 29(23):3313-23. DOI: 10.1038/onc.2010.109. View